Title	HIV & HTLV-I Associated Malignancies [electronic resource] / edited by Joseph A. Sparano
Imprint	Boston, MA : Springer US : Imprint: Springer, 2001
Connect to	http://dx.doi.org/10.1007/978-1-4615-1601-9
Descript	XII, 378 p. online resource

Infection with the human immunodeficiency virus (HIV) and human T-cell lymphotropic virus type I (HTLV-I) is known to be associated with an increased risk of neoplastic disorders, especially Kaposi's sarcoma and aggressive B-cell lymphoma for the former, and T-cell lymphoma for the latter. The information obtained from the study of these infections has led to remarkable advances in our understanding of the immune system, as well as the biology of human neoplasms. The management of malignant diseases in such patients also poses substantial challenges to clinicians. This book provides an overview of the epidemiology, biology, clinical features, and clinical management of neoplasms occurring in such individuals. It is an important resource for clinicians treating these diseases, and for basic scientists who have an interest in this field

1. Epidemiology of HIV-Associated Malignancies -- 2. Immunopathogenesis of HIV and HTLV-I Infection:Mechanisms for Lymphomagenesis -- 3. HTLV-I Associated Leukemia/Lymphoma:Epidemiology, Biology, and Treatment -- 4. Biology of Kaposiโ{128}{153}s Sarcoma -- 5. Treatment of Kaposiโ{128}{153}s Sarcoma -- 6. Biology of Non-Hodgkinโ{128}{153}s Lymphoma -- 7. Non-Hodgkinโ{128}{153}s Lymphoma: Pathogenesis,Clinical Presentation, and Treatment -- 8. Primary Central Nervous System Lymphoma -- 9. Hodgkinโ{128}{153}s Disease: Clinical Presentation and Treatment -- 10. Biology of Anogenital Neoplasia -- 11. Management of Cervical Neoplasia -- 12. Non-AIDS-Defining Malignancies -- 13. Hematopoiesis in HIV Infection:Use of Colony Stimulating Factors and Cytokines -- 14. Special Considerations Regarding Antiretroviral Therapyand Infection Prophylaxis in theHIV-Infected Individual with Cancer -- 15. AIDS Malignancy Clinical Research:Resources of the National Cancer Institute